title: Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.
abstract: Non-Hodgkin lymphomas account for approximately 7% of cancers diagnosed in patients less than 20 years of age, with approximately 800 cases diagnosed annually at COG institutions. With current therapies, cure rates range from 70% to over 90%, even for children with disseminated disease. However, two major challenges need to be overcome: (i) to optimize upfront treatment to prevent relapse since prognosis for patients with relapsed disease remains poor and (ii) minimize long-term side effects in survivors. Hence, the future initiatives for the treatment of pediatric NHL are to utilize novel targeted therapies to not only improve outcomes but to decrease bystander organ toxicities and late effects.
authors.affiliation: Division of Pediatric Hematology and Oncology, Department of Pediatrics, Texas Children's Hospital and Baylor College of Medicine, Houston, TX 77030, USA. cmbollar@txch.org
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.forename: Megan S
authors.initials: MS
authors.lastname: Lim
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Gross
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D012106:Research
chemical_list: D000970:Antineoplastic Agents